SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

Accueil・Liste d'Actions・Pharma Mar SA

P
Pharma Mar SA

Fermé

96 -1.39

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

95.65

Max

97.4

Chiffres clés
By Trading Economics
Revenu	-58M 1.6M
Ventes	-48M 43M
P/E Moyenne du Secteur	21.171 51.415
BPA	0.088
Marge bénéficiaire	3.725
Employés	505
EBITDA	-40M 2.7M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+23.2% upside

Dividendes
By Dow Jones
Prochains Résultats	29 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	35M 1.7B
Ouverture précédente	97.39
Clôture précédente	96

Score Technique

By Trading Central

Confiance

Bearish Evidence

72.75 / 74.3 Support & Résistance

Pharma Mar SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mai 2026, 16:02 UTC

Résultats

Principaux Mouvements du Marché

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mai 2026, 14:55 UTC

Principaux Mouvements du Marché

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mai 2026, 14:43 UTC

Principaux Mouvements du Marché

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mai 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mai 2026, 16:24 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 mai 2026, 15:20 UTC

Résultats

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mai 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparaison

Variation de prix

Pharma Mar SA prévision

Objectif de Prix

By TipRanks

23.2% hausse

Prévisions sur 12 Mois

Moyen 120.243 EUR 23.2%

Haut 120.742 EUR

Bas 119.744 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

72.75 / 74.3Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

All events are bullish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.